This disclosure is directed, at least in part, to SSTR5 antagonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the SSTR5 antagonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

The present invention falls within the field of medical chemistry and relates to a class of compounds as SHP2 inhibitors and the use thereof. Specifically, the present invention provides a compound represented by formula (I), or an isomer, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug thereof, a preparation method therefor, a pharmaceutical composition comprising the compounds, and the use of the compounds or the composition for treating a disease mediated by SHP2.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

The disclosure is directed to compounds of Formula I

##STR00001##

Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.

The disclosure is directed to compounds of Formula I

##STR00001##

Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.

The invention relates to carboxamide-pyrimidine derivatives of the general formula I, ##STR00001##
or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

The invention relates to carboxamide-pyrimidine derivatives of the general formula I, ##STR00001##
or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrazine compound, a pharmaceutical composition comprising same, and the use thereof. In particular, the present invention relates to a compound with the structure of formula (I), which exhibits a good SHP2 inhibiting activity, and can act as an efficient SHP2 inhibitor for preventing and/or treating SHP2-related diseases.

##STR00001##

An electrolytic capacitor includes a capacitor element, a solid electrolyte layer, an electrolyte solution. The capacitor element has an anode foil with a dielectric layer, and a cathode foil. The solid electrolyte layer is provided between the anode foil and the cathode foil. And the capacitor element is impregnated with the electrolyte solution. The cathode foil includes a covering layer that contains at least one metal selected from titanium and nickel or a compound of the at least one metal. And the solid electrolyte layer contains a conductive polymer, a polymer dopant, and a base component.